



Innovative Medicines Initiative

# Report of the Interim Review

**[Full Project Title]**

**[Acronym]**

**[Grant Agreement No]**

**[Name of the Coordinator]**

**[Coordinator Institution]**  
**[Coordinator Contact Details]**

Project starting date:

Project duration:

Period covered by the interim review report, [month/year] - [month/year]

Date and place of review meeting:

Name of the IMI Scientific Manager:

Name (s) of the expert(s):

Signature(s):

Date:



efpia



## **1. OVERALL ASSESSMENT**

### a. Achievements:

This section will include comments, in particular highlighting the scientific/technical achievements of the project, its contribution to the State of the Art and its impact.

*Comments*

### b. Overall recommendations:

This section will include overall recommendations (e.g. on overall modifications, corrective actions at work package level, or re-tuning the objectives to optimise the impact or keep up with the State of the Art, or for other reasons, like best use of resources, re-focusing...).

It will also include views on the sustainability of the project.

*Comments*

## **2. PROGRESS AGAINST OBJECTIVES**

### a. Progress towards project objectives:

Have the objectives for the period been achieved? In particular, has the project as a whole been making satisfactory progress in relation to the Description of Work (Annex I to the grant agreement)?

*Comments*

b. Progress in individual work packages:  
Has each work package (WP) been making satisfactory progress in relation to the Description of Work (Annex I of the grant agreement)?

*Comments*

c. Milestones and deliverables:  
Have planned milestones and deliverables been achieved for the reporting period?

*Comments*

d. Deviations from Description of work (Annex I): In case of any major deviations from Description of Work, have these been adequately addressed and justified?

*Comments*

### **3. MAJOR ACHIEVEMENTS AND DISSEMINATION**

a. Impact: Comment on the major achievements at this stage of the project.  
Is there evidence that the project has/will have the potential to be rapidly and broadly spread and taken up within the scientific/industrial community?

*Comments*

a1. If relevant, is there an impact on participating EFPIA companies, Small and Medium Enterprises (SMEs), Academia yet?

*Comments*

b. Dissemination: Has the consortium disseminated project results and information adequately (patent application, publications, abstracts, conferences, lay audience, website...)?

*Comments*

c. Please identify potential information that should be disseminated to:

- Policy makers
- The scientific community
- The general public
- A specific group of end users

d. Use and dissemination of foreground: Please comment on the plan for the exploitation and use of foreground for the consortium as a whole, or for individual beneficiary or groups of beneficiaries and its progress to date.

*Comments*

#### **4. MANAGEMENT OF PROJECT AND CONSORTIUM**

a. Management: Has the project management been performed adequately?

*Comments*

b. Has the collaboration in the consortium between stakeholders (EFPIA/ academics/ SMEs /patients organisations/ regulatory authorities) been effective? Do you see an added value of the public private partnership (PPP) in the context of this project?

*Comments*

c.1 IMI JU beneficiaries and other participants: How do you see their commitment and interest in the project?

*Comments*

c.2 EFPIA participants: How do you see the commitment and interest of EFPIA participants?

*Comments*

- d. Synergies with other projects: Have the synergies been effective or would you recommend any synergies?

*Comments*

- e. Relevance of the project plan for the coming periods: Are the objectives/key activities, milestones and deliverables for the coming period(s) i) still relevant and ii) still achievable within the time and resources available to the project?

*Comments*

- f. Risk assessment for the upcoming period: Are key risks if any well identified and mitigation plan related adequate?

*Comments*

- g. Sustainability of the project: Has the consortium addressed the sustainability of the project beyond the funding period and described any action?

*Comments*

## **5. RESOURCES**

- a. Assessment of the use of resources: IMI JU financial contribution and in kind contribution: To the best of your estimate, have the IMI JU financial contribution and in kind contribution been utilised for achieving the progress of the project.

*Comments*

- b. Deviations from original budget: If applicable, please comment on major deviations with respect to the planned resources.

*Comments*

## **6. OTHER ISSUES**

If applicable comment on whether other relevant issues (e.g. ethical, policy-related/regulatory, safety) have been handled appropriately.

*Comments*